vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $180.9M, roughly 1.0× AVANOS MEDICAL, INC.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -0.7%, a 48.7% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -21.9%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -15.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AVNS vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $188.3M |
| Net Profit | $-1.3M | $90.3M |
| Gross Margin | 47.5% | 79.5% |
| Operating Margin | 1.4% | 32.3% |
| Net Margin | -0.7% | 47.9% |
| Revenue YoY | 0.7% | -21.9% |
| Net Profit YoY | 99.7% | 1710.8% |
| EPS (diluted) | $-0.02 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $188.3M | ||
| Q3 25 | $177.8M | $215.3M | ||
| Q2 25 | $175.0M | $188.2M | ||
| Q1 25 | $167.5M | $197.2M | ||
| Q4 24 | $179.6M | $241.0M | ||
| Q3 24 | $170.4M | $225.5M | ||
| Q2 24 | $171.7M | $256.0M | ||
| Q1 24 | $166.1M | $263.4M |
| Q4 25 | $-1.3M | $90.3M | ||
| Q3 25 | $-1.4M | $91.1M | ||
| Q2 25 | $-76.8M | $139.5M | ||
| Q1 25 | $6.6M | $-10.0M | ||
| Q4 24 | $-397.3M | $-5.6M | ||
| Q3 24 | $4.3M | $-284.4M | ||
| Q2 24 | $1.8M | $-433.6M | ||
| Q1 24 | $-900.0K | $-49.2M |
| Q4 25 | 47.5% | 79.5% | ||
| Q3 25 | 48.4% | 83.7% | ||
| Q2 25 | 52.6% | 81.3% | ||
| Q1 25 | 53.6% | 81.4% | ||
| Q4 24 | 54.6% | 79.8% | ||
| Q3 24 | 54.5% | 82.1% | ||
| Q2 24 | 55.7% | 84.5% | ||
| Q1 24 | 57.1% | 85.3% |
| Q4 25 | 1.4% | 32.3% | ||
| Q3 25 | 0.1% | 30.4% | ||
| Q2 25 | -42.6% | 5.7% | ||
| Q1 25 | 6.1% | -31.2% | ||
| Q4 24 | -233.0% | -69.2% | ||
| Q3 24 | 7.0% | -36.4% | ||
| Q2 24 | 3.7% | -90.8% | ||
| Q1 24 | 2.4% | -6.1% |
| Q4 25 | -0.7% | 47.9% | ||
| Q3 25 | -0.8% | 42.3% | ||
| Q2 25 | -43.9% | 74.1% | ||
| Q1 25 | 3.9% | -5.1% | ||
| Q4 24 | -221.2% | -2.3% | ||
| Q3 24 | 2.5% | -126.1% | ||
| Q2 24 | 1.0% | -169.4% | ||
| Q1 24 | -0.5% | -18.7% |
| Q4 25 | $-0.02 | $2.78 | ||
| Q3 25 | $-0.03 | $2.91 | ||
| Q2 25 | $-1.66 | $4.50 | ||
| Q1 25 | $0.14 | $-0.39 | ||
| Q4 24 | $-8.64 | $-0.01 | ||
| Q3 24 | $0.09 | $-9.39 | ||
| Q2 24 | $0.04 | $-14.35 | ||
| Q1 24 | $-0.02 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $226.6M |
| Total DebtLower is stronger | $90.3M | $1.4B |
| Stockholders' EquityBook value | $778.2M | $-171.5M |
| Total Assets | $1.1B | $1.7B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $226.6M | ||
| Q3 25 | $70.5M | $184.2M | ||
| Q2 25 | $90.3M | $267.4M | ||
| Q1 25 | $97.0M | $138.3M | ||
| Q4 24 | $107.7M | $146.9M | ||
| Q3 24 | $89.0M | $159.2M | ||
| Q2 24 | $92.2M | $236.9M | ||
| Q1 24 | $75.8M | $190.7M |
| Q4 25 | $90.3M | $1.4B | ||
| Q3 25 | $93.4M | $1.3B | ||
| Q2 25 | $95.7M | $1.3B | ||
| Q1 25 | $98.0M | $1.4B | ||
| Q4 24 | $125.3M | $1.5B | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $-171.5M | ||
| Q3 25 | $778.0M | $-260.5M | ||
| Q2 25 | $776.3M | $-351.7M | ||
| Q1 25 | $839.4M | $-496.8M | ||
| Q4 24 | $828.5M | $-488.2M | ||
| Q3 24 | $1.2B | $-497.6M | ||
| Q2 24 | $1.2B | $-218.3M | ||
| Q1 24 | $1.2B | $228.4M |
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $1.7B | $2.2B | ||
| Q2 24 | $1.7B | $3.2B | ||
| Q1 24 | $1.7B | $5.0B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $26.2M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $26.2M | ||
| Q3 25 | $14.0M | $-60.6M | ||
| Q2 25 | $6.8M | $-25.6M | ||
| Q1 25 | $25.7M | $184.0K | ||
| Q4 24 | $57.9M | $-2.7M | ||
| Q3 24 | $23.0M | $19.5M | ||
| Q2 24 | $27.8M | $111.5M | ||
| Q1 24 | $-8.0M | $135.4M |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
